PEP-CMV Component B

PEP-CMV Component B is a component of the investigational peptide vaccine known as PEP-CMV, which targets the human cytomegalovirus (CMV) antigen pp65. The full vaccine (PEP-CMV) is designed as an immunotherapy for pediatric and young adult patients with recurrent medulloblastoma, high-grade glioma (HGG), and diffuse intrinsic pontine glioma (DIPG). The main described component in public sources is "Component A," a synthetic long peptide of 26 amino acids derived from CMV pp65, formulated in Montanide ISA 51. There is no detailed public information specifically describing "Component B"—its sequence, function, or whether it represents another peptide or adjuvant within the formulation. It may be an additional synthetic peptide targeting another epitope of CMV or a formulation element distinct from "Component A." As such, its mechanism would be presumed similar to that of other components in the vaccine—eliciting an immune response against CMV antigens present on tumor cells[3][4][5][6].

Brand names

PEP-CMV Component B

Other names

PEP-CMV Component B